EMBO Molecular Medicine · 2010 · 232 citations · 53 references
MedicineHematologyOncologyImmunogeneticsMolecular OncologyOncogenesHematologic Malignancy TherapyBcr-abl1 Fusion Gene
Tumourigenesis caused by the Bcr/Abl oncoprotein is a multi-step process proceeding from initial to tumour-maintaining events and finally results in a complex tumour-supporting network. A key to successful cancer therapy is the identification of critical functional nodes in an oncogenic network required for disease maintenance. So far, the transcription factors Stat3 and Stat5a/b have been implicated in bcr/abl-induced initial transformation. However, to qualify as a potential drug target, a signalling pathway must be required for the maintenance of the leukaemic state. Data on the roles of Stat3 or Stat5a/b in leukaemia maintenance are elusive. Here, we show that both, Stat3 and Stat5 are necessary for initial transformation. However, Stat5- but not Stat3-deletion induces G(0)/G(1) cell cycle arrest and apoptosis of imatinib-sensitive and imatinib-resistant stable leukaemic cells in vitro. Accordingly, Stat5-abrogation led to effective elimination of myeloid and lymphoid leukaemia maintenance in vivo. Hence, we identified Stat5 as a vulnerable point in the oncogenic network downstream of Bcr/Abl representing a case of non-oncogene addiction (NOA).
53
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations
Brian Druker, Charles L. Sawyers, Hagop M. Kantarjian et al. · New England Journal of Medicine · 2001 · 2.7K citations · Full text
Medicine, Hematology, Oncology +17
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura, David G. Kirsch, Margaret E. McLaughlin et al. · Nature · 2007 · 1.8K citations
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo, Nicole L. Solimini, Stephen J. Elledge · Cell · 2009 · 1.8K citations · Full text
Medicine, Cancer Biology, Oncology +14